Autoimmune hepatitis

Board exam relevance: in 7 of more than 100 exam reports · rank 53
Synonyms
AIH, autoimmune liver inflammation, lupoid hepatitis, autoimmune chronic active hepatitis
Specialty
Internal medicine · Liver & biliary tract
Images
Histology 2
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Occurrence & epidemiology
  5. Aetiopathogenesis
  6. Clinical features
  7. Histology
  8. Diagnosis
  9. Treatment principles
  10. Keep learning in the app
  11. Further reading (open access)
  12. Cross-references

Images (2)

Autoimmune hepatitis – Histology (H&E): autoimmune hepatitis with lymphoplasmacytic interface hepatitis at the border between portal tract and liver parenchymaHistology
Histology (H&E): autoimmune hepatitis with lymphoplasmacytic interface hepatitis at the border between portal tract and liver parenchymaImage: Nephron, “Autoimmune hepatitis - intermed mag” (Wikimedia Commons) · CC BY-SA 3.0 · Source
Autoimmune hepatitis – Histology (H&E), higher magnification: interface hepatitis – inflammatory cells spill over from the portal tract into adjacent hepatocytesHistology
Histology (H&E), higher magnification: interface hepatitis – inflammatory cells spill over from the portal tract into adjacent hepatocytesImage: Nephron, “Interface hepatitis -- high mag” (Wikimedia Commons) · CC BY-SA 3.0 · Source
1 / 2

Definition

Autoimmune hepatitis (AIH) is a chronic, immune-mediated inflammation of the liver parenchyma. It is characterised by raised aminotransferases, raised IgG, circulating autoantibodies and interface hepatitis on histology. There is no single confirmatory test; the diagnosis is based on the combination of clinical, laboratory and histological findings after exclusion of other causes.

Classification

According to the autoantibody profile, the following are distinguished:

  • AIH type 1: antinuclear antibodies (ANA), smooth muscle antibodies (SMA, anti-actin) and/or anti-SLA/LP; with about 70% of patients the most common form
  • AIH type 2: antibodies to liver-kidney microsomes (anti-LKM1) and/or anti-LC1; about 10% of patients

Anti-SLA/LP has the highest disease specificity. Overlap with PBC or PSC occurs (variant syndromes).

Occurrence & epidemiology

The incidence of AIH in Europe is about 1–2 per 100,000 persons per year, and the prevalence about 10–30 per 100,000. Around 80% of those affected are women. The disease occurs at any age, with a peak of first manifestation between 40 and 70 years.

Aetiopathogenesis

The cause is not fully understood. In genetically predisposed individuals, among others with the HLA types DR3 and DR4, a misdirected T-cell-mediated immune reaction is directed against liver cells. Clustering with other autoimmune diseases is typical:

  • autoimmune thyroiditis (Hashimoto's) in 10–23%
  • ulcerative colitis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus
  • celiac disease, type 1 diabetes, vitiligo
  • PBC or PSC as overlap

Clinical features

The spectrum ranges from asymptomatic raised liver values through insidious chronic hepatitis to acute icteric hepatitis and fulminant liver failure. With an insidious onset, fatigue and exhaustion predominate. Arthralgia is common; in young women, further manifestations such as acne, amenorrhoea and thyroiditis occur.

At diagnosis, 20–37% of patients already have liver cirrhosis, more often in symptomatic than in asymptomatic patients.

Histology

The key finding is interface hepatitis: a lymphocytic or lymphoplasmacytic infiltrate of the portal tracts crosses the limiting plate and extends into the lobule. Hepatocyte rosettes and single-cell necroses are also seen. In acute first presentation, perivenular necrosis and lobular inflammation are often present; bile duct changes argue against AIH.

Diagnosis

  • Laboratory tests: raised aminotransferases, typically raised IgG; testing for ANA, SMA, anti-LKM1 and anti-SLA/LP; TSH because of frequent thyroid involvement
  • Exclusion of other causes: viral hepatitis, drug-induced or toxic injury, alcohol, Wilson's disease, fatty liver disease
  • Ultrasound and non-invasive fibrosis assessment
  • Liver biopsy: usually to confirm the diagnosis and assess inflammatory activity

Diagnostic score

The simplified AIH score (Hennes 2008) supports the diagnosis:

  • Autoantibodies: ANA or SMA of 1:40 or more (1 point); ANA or SMA of 1:80 or more, LKM of 1:40 or more or SLA/LP positive (2 points); at most 2 points
  • IgG: above normal (1 point), above 1.1 times normal (2 points)
  • Histology: compatible with AIH (1 point), typical of AIH (2 points)
  • Absence of viral hepatitis: 2 points

From 6 points AIH is probable, from 7 points it is considered definite. The more detailed revised score of the International Autoimmune Hepatitis Group also exists.

Treatment principles

  • Remission is induced with glucocorticoids, usually combined with a thiopurine as a steroid-sparing immunosuppressant.
  • The goal is complete biochemical remission, secured by long-term maintenance therapy; withdrawal is considered only after prolonged stable remission with close monitoring.
  • Second-line immunosuppressants are available for intolerance or treatment failure, and liver transplantation should be considered in acute liver failure or decompensated cirrhosis.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Autoimmune hepatitis with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. DGVS/AWMF 021-027: S2k-Leitlinie Autoimmune Lebererkrankungen (Stand 2017)
  2. MSD Manual Professional: Overview of Chronic Hepatitis

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Liver cirrhosis · Primary biliary cholangitis (PBC) · Esophageal varices and portal hypertension

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.